Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

The Home Depot Announces Receipt of Clearance from the Canadian Competition Bureau for Acquisition of GMS Inc.

(NYSE:HD) ATLANTA, Aug. 29, 2025 /PRNewswire/ -- The Home DepotÂź announced today that it has received clearance from the Canadian Competition Bureau, in the form of a no action letter, in connectio...

How will the deal impact Home Depot's balance sheet, cash position, and dividend policy in the near term? Does the clearance from the Canadian Competition Bureau remove all regulatory risk, or are there additional approvals required in other jurisdictions? What are the expected synergies and cost savings from the GMS Inc. acquisition and how will they affect Home Depot's earnings per share?
Symbol: HD
Mergers
1 day ago
Read more prnewswire

Seminar: IP That Matters - Behind Orexo's Milestone Patent Win at the US Court

(ORX) UPPSALA, Sweden, Aug. 29, 2025 /PRNewswire/ -- Orexo (publ.), (STO: ORX) (OTCQX: ORXOY) in collaboration with its advisory international law firms Potter Clarkson LLP and Steptoe LLP, will ho...

What is the likelihood that the strategies discussed will lead to new licensing deals or partnerships that could boost the stock price? Will this legal victory give Orexo a competitive advantage over peers in the pharmaceutical space, and could it affect market share? How might the seminar and highlighted patent win influence Orexo's future revenue and earnings forecasts?
Symbol: ORX
Legal
1 day ago
Read more prnewswire

Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

(NASDAQ:ESPR) – Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence –

How does this endorsement position bempedoic acid against competing lipid‑lowering therapies such as PCSK9 inhibitors and statins in terms of market share and pricing power? What is the expected timeline for commercial rollout and payer coverage of bempedoic acid following the guideline endorsement? How will the ESC/EAS Level 1a recommendation affect Esperion's revenue outlook and stock valuation?
Symbol: ESPR
Guidelines
1 day ago
Read more globenewswire

Vaxart Granted Extension by Nasdaq to Regain Compliance

(VAXR) - Company must regain compliance with the Nasdaq Bid Price Rule on or before the October 17, 2025 deadline -

How does this compliance situation compare to similar cases among peer biotech companies and what could it mean for long‑term investor confidence? What specific measures is Vaxart implementing to meet the Nasdaq Bid Price Rule by the Oct 17, 2025 deadline? How will the extension affect Vaxart's liquidity and short‑term price movement?
Symbol: VAXR
Regulation
1 day ago
Read more globenewswire